Jay Moyes stepping down from the board is a positive step as he was out of line with the rest of the company as his resignation letter points out. The whole stemcell market place is becoming harder to operate in so why Moyes would think he knows better is beyond me but everyone had their own opinions.
The fact that the company posted his letter is a clear sign that they wanted it out there and it shows a willingness towards transparency which is to be welcomed.
As pointed out by others here, it’s better to rely on the informed opinion of industry leaders in the form of sorintino and co. Moyes space will be taken up no doubt with somebody with real expertise and better to have a company all going the same direction rather than a rogue element fighting against them making life difficult.
The way he wrote this letter smacks of anger and petulance which is in keeping with various reports on Moyes personality. A door closes and another opens.
Fundamentals still very much in play. As I mentioned in a post a few days ago, the magic ingredient here is the genetic platform that Pred has. Largest, most diverse genetic disease platform in the world which can be used in multiple fields across an array of illnesses. That will eventually register with people.
Added to that is the diagnostics and no doubt therapeutics that will follow. I see pred doing business with multiple groups in different fields who need to use their platform. That will result in multiple revenue streams added to their women’s health focus. The future is bright.
In the short term, I know the company is at JP Morgan next week and as with history, they normally go into things like that with significant news . Stock action would suggest buyers becoming more aggressive and lone may it continue.
As always, do your own DD, pick up the phone, ask questions. Understand what you have and be happy
I’m limited to one post per day hence no replies
